» Articles » PMID: 22487321

CD73: a Potent Suppressor of Antitumor Immune Responses

Overview
Journal Trends Immunol
Date 2012 Apr 11
PMID 22487321
Citations 207
Authors
Affiliations
Soon will be listed here.
Abstract

Tumors use several strategies to evade immunosurveillance. One such mechanism is the generation of adenosine within the tumor microenvironment, which potently suppresses antitumor T cell responses. Adenosine within the tumor is generated by CD73, a membrane-bound nucleotidase that is expressed by tumor cells, suppressive immune subsets such as T regulatory cells (Tregs) and myeloid-derived suppressor cells and endothelial cells. Recent evidence suggests that targeted inhibition of CD73 has the potential to reduce tumorigenesis and metastasis, as well as enhancing the potency of T-cell-directed therapies. This review outlines the impact of adenosine on suppressing the antitumor response and the evidence supporting the rationale for CD73 targeting in the treatment of cancer.

Citing Articles

Divergent response to radio-immunotherapy is defined by intrinsic features of the tumor microenvironment.

Gadwa J, Yu J, Piper M, Knitz M, Darragh L, Olimpo N J Immunother Cancer. 2025; 13(1).

PMID: 39773568 PMC: 11749720. DOI: 10.1136/jitc-2024-010405.


Biological Functions and Therapeutic Potential of NAD Metabolism in Gynecological Cancers.

Myong S, Nguyen A, Challa S Cancers (Basel). 2024; 16(17).

PMID: 39272943 PMC: 11394644. DOI: 10.3390/cancers16173085.


Enhancing Chemotherapy Efficacy: Investigating the Synergistic Impact of Paclitaxel and cd73 Gene Suppression on Breast Cancer Cell Proliferation and Migration.

Hamidnia F, Aslan E, Najafi S, Baghbani E, Eslamkhah S, Baradaran B Cureus. 2024; 16(7):e65027.

PMID: 39165432 PMC: 11334381. DOI: 10.7759/cureus.65027.


Remodeling of the bone marrow microenvironment during acute myeloid leukemia progression.

Urs A, Goda C, Kulkarni R Ann Transl Med. 2024; 12(4):63.

PMID: 39118939 PMC: 11304419. DOI: 10.21037/atm-23-1824.


A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.

Coveler A, Reilley M, Zalupski M, Macarulla T, Fountzilas C, Ponz-Sarvise M Clin Cancer Res. 2024; 30(20):4609-4617.

PMID: 39106081 PMC: 11474165. DOI: 10.1158/1078-0432.CCR-24-0499.